Larry L. Augsburger, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Larry L. Augsburger, PhD


Larry L. Augsburger, PhD, is a Pharmtech editorial advisory board (EAB) member

Larry L. Augsburger, PhD
Professor, Department of
Pharmaceutics
University of Maryland

Augsburger is an emeritus professor at the University of Maryland School of Pharmacy. He previously served as the Shangraw Professor of Industrial Pharmacy and Pharmaceutics, chair of the department of pharmaceutics and director of pharmaceutics graduate programs. He has overseen graduate and postdoctoral student research in the areas of design and optimization of immediate release and extended release oral solid dosage forms, the functionality of excipients, the instrumentation of pharmaceutical processing equipment, and botanical dietary supplement product development and quality.

Augsburger established the Drug Development Facility in the school of pharmacy, which later became UPM Pharmaceuticals, Inc., a university-affiliated for-profit firm for developing drugs and manufacturing clinical supplies. A founding father of UPM, he served for five years as its vice-president of pharmaceutical development and manufacture.

He was a principal investigator and directed the research programs of the $12-million University of Maryland-FDA Collaborative Agreements that led to the development of SUPAC regulatory policies for immediate- and modified-release oral solid dosage forms. Augsburger is an elected fellow and former president of the American Association of Pharmaceutical Scientists (AAPS). Among his awards are the Federation Internationale Pharmaceutique (FIP) Industrial Pharmacy medal, the FDA Commissioner's Special Citation, the AAPS Research Achievement Award and the AAPS Outstanding Educator Award.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here